Slow-release vaginal insert of misoprostol vs orally administrated solution of misoprostol for the induction of labour in primiparous term pregnant women: A randomized controlled trial
BJOG: An International Journal of Obstetrics and Gynaecology May 23, 2019
Wallström T, et al. - In this open-label, randomized controlled trial, the World Health Organization recommended orally administrated dosage of misoprostol (25 μg) was compared with a vaginal slow-release (7 μg/hours) insert of misoprostol with respect to the time from induction to delivery and safety of the method. Researchers randomized 196 primiparous women with singletons in a cephalic presentation at ≥37 weeks of gestation and with a Bishop score of ≤4, to an oral solution of misoprostol (Cytotec n = 99) or vaginal slow-release misoprostol [Misodel n = 97]. Outcomes revealed no shorter time from induction to vaginal-delivery but a higher risk for hyperstimulation and fetal distress in vaginal delivery after induction of labor with slow-release misoprostol vs oral misoprostol solution. No differences in mode of delivery or neonatal outcome were evident.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries